PubRank

Oligonucleotides

Journal PubWeight™ 205.71‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Analysis of thermal melting curves. 2003 2.84
2 siRNA and innate immunity. 2009 2.28
3 Chemical modification of siRNAs for in vivo use. 2008 2.03
4 Therapeutic applications of DNA and RNA aptamers. 2009 1.59
5 Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. 2005 1.42
6 Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. 2007 1.40
7 Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. 2004 1.37
8 Therapeutic potential of splice-switching oligonucleotides. 2009 1.24
9 The translation start codon region is sensitive to antisense PNA inhibition in Escherichia coli. 2003 1.24
10 Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. 2003 1.20
11 Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. 2007 1.20
12 Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. 2008 1.17
13 Insights into effective RNAi gained from large-scale siRNA validation screening. 2007 1.16
14 Double-stranded break can be repaired by single-stranded oligonucleotides via the ATM/ATR pathway in mammalian cells. 2008 1.13
15 RNA-directed transcriptional gene silencing and activation in human cells. 2009 1.13
16 The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. 2010 1.13
17 Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. 2007 1.12
18 Cell-specific aptamer-mediated targeted drug delivery. 2010 1.10
19 Cellular uptake and localization of a Cy3-labeled siRNA specific for the serine/threonine kinase Pim-1. 2003 1.10
20 Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). 2006 1.09
21 Characterization of modified antisense oligonucleotides in Xenopus laevis embryos. 2006 1.08
22 Conserved microRNA characteristics in mammals. 2006 1.08
23 Stability study of unmodified siRNA and relevance to clinical use. 2008 1.08
24 Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect. 2009 1.08
25 Small fragment homologous replacement-mediated modification of genomic beta-globin sequences in human hematopoietic stem/progenitor cells. 2006 1.07
26 shRNAs targeting hepatitis C: effects of sequence and structural features, and comparision with siRNA. 2007 1.05
27 Advances in aptamers. 2010 1.05
28 Stem-loop RT-PCR quantification of siRNAs in vitro and in vivo. 2009 1.05
29 Strategies for generation of an siRNA expression library directed against the human genome. 2003 1.04
30 RNA interference from multimeric shRNAs generated by rolling circle transcription. 2006 1.02
31 Decoy-DNA against special AT-rich sequence binding protein 1 inhibits the growth and invasive ability of human breast cancer. 2011 1.00
32 Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing. 2010 1.00
33 G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. 2006 0.99
34 Evaluation of transfection protocols for unmodified and modified peptide nucleic acid (PNA) oligomers. 2006 0.97
35 Base pairing properties of D- and L-cyclohexene nucleic acids (CeNA). 2003 0.97
36 Direct CNS delivery of siRNA mediates robust silencing in oligodendrocytes. 2009 0.97
37 Targeting CCR5 with siRNAs: using recombinant SV40-derived vectors to protect macrophages and microglia from R5-tropic HIV. 2003 0.96
38 Induction of apoptosis in murine neuroblastoma by systemic delivery of transferrin-shielded siRNA polyplexes for downregulation of Ran. 2008 0.96
39 A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. 2010 0.96
40 Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues. 2005 0.96
41 Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). 2004 0.96
42 A web-based search engine for triplex-forming oligonucleotide target sequences. 2006 0.96
43 Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. 2003 0.95
44 Molecular imaging study on in vivo distribution and pharmacokinetics of modified small interfering RNAs (siRNAs). 2008 0.95
45 Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis. 2004 0.94
46 Modification of alternative splicing by antisense therapeutics. 2004 0.94
47 Antimetastatic potential of PAI-1-specific RNA aptamers. 2009 0.93
48 Comparison of different strategies to select aptamers against a transmembrane protein target. 2006 0.93
49 Streptavidin-coated magnetic beads for DNA strand separation implicate a multitude of problems during cell-SELEX. 2009 0.93
50 A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2'-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA, or 2'-thio-LNA residues. 2003 0.92
Next 50